Pfizer is expected to announce today its plans to back a large-scale clinical trial to test the arthritis drug's ability to prevent heart attacks and strokes in people with serious cardiovascular disease. The trial is seen as a big bet on Celebrex, because if it dampens inflammation and protects the heart use of Celebrex could increase, while negative results could hurt sales of the $3 billion-a-year drug.

Related Summaries